Tao Wu

A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma

Y. Cheng, B. Tan, L. Bie, 2022, BMC medicine.

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.

G. Jiang, Q. Fan, Feng Zhao, 2022, The lancet. Gastroenterology & hepatology.

Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.

Yufeng Cheng, Y. Hong, S. Luo, 2021 .